229 related articles for article (PubMed ID: 26548546)
1. Using 'big data' to validate claims made in the pharmaceutical approval process.
Wasser T; Haynes K; Barron J; Cziraky M
J Med Econ; 2015; 18(12):1013-9. PubMed ID: 26548546
[TBL] [Abstract][Full Text] [Related]
2. Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned.
Carnahan RM; Moores KG
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():82-9. PubMed ID: 22262596
[TBL] [Abstract][Full Text] [Related]
3. Validation of modeled pharmacoeconomic claims in formulary submissions.
Langley PC
J Med Econ; 2015; 18(12):993-9. PubMed ID: 26549802
[TBL] [Abstract][Full Text] [Related]
4. Validating pharmaceutical product claims: questions a formulary committee should ask.
Schommer JC; Carlson AM; Rhee TG
J Med Econ; 2015; 18(12):1000-6. PubMed ID: 26548326
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of risk management plans: a case study of pemoline using pharmacy claims data.
Morrato EH; Staffa JA
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):104-12. PubMed ID: 16821248
[TBL] [Abstract][Full Text] [Related]
6. Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative data: summary of findings and suggestions for future research.
Carnahan RM
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():90-9. PubMed ID: 22262597
[TBL] [Abstract][Full Text] [Related]
7. Usage of the claim database of national health insurance programme for analysis of cisapride-erythromycin co-medication in Taiwan.
Gau CS; Chang IS; Lin Wu FL; Yu HT; Huang YW; Chi CL; Chien SY; Lin KM; Liu MY; Wang HP
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):86-95. PubMed ID: 17006967
[TBL] [Abstract][Full Text] [Related]
8. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership.
Ryan PB; Madigan D; Stang PE; Overhage JM; Racoosin JA; Hartzema AG
Stat Med; 2012 Dec; 31(30):4401-15. PubMed ID: 23015364
[TBL] [Abstract][Full Text] [Related]
9. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of validated methods for identifying hypersensitivity reactions other than anaphylaxis (fever, rash, and lymphadenopathy), using administrative and claims data.
Schneider G; Kachroo S; Jones N; Crean S; Rotella P; Avetisyan R; Reynolds MW
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():248-55. PubMed ID: 22262613
[TBL] [Abstract][Full Text] [Related]
11. Do falls and falls-injuries in hospital indicate negligent care -- and how big is the risk? A retrospective analysis of the NHS Litigation Authority Database of clinical negligence claims, resulting from falls in hospitals in England 1995 to 2006.
Oliver D; Killick S; Even T; Willmott M
Qual Saf Health Care; 2008 Dec; 17(6):431-6. PubMed ID: 19064658
[TBL] [Abstract][Full Text] [Related]
12. Active influenza vaccine safety surveillance: potential within a healthcare claims environment.
Brown JS; Moore KM; Braun MM; Ziyadeh N; Chan KA; Lee GM; Kulldorff M; Walker AM; Platt R
Med Care; 2009 Dec; 47(12):1251-7. PubMed ID: 19786905
[TBL] [Abstract][Full Text] [Related]
13. Early detection of adverse drug events within population-based health networks: application of sequential testing methods.
Brown JS; Kulldorff M; Chan KA; Davis RL; Graham D; Pettus PT; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1275-84. PubMed ID: 17955500
[TBL] [Abstract][Full Text] [Related]
14. Postmarketing surveillance of medical devices using Medicare claims.
Malenka DJ; Kaplan AV; Sharp SM; Wennberg JE
Health Aff (Millwood); 2005; 24(4):928-37. PubMed ID: 16012135
[TBL] [Abstract][Full Text] [Related]
15. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
16. Utilizing Medicare claims data for real‐time drug safety evaluations:is it feasible?
Hartzema AG; Racoosin JA; MaCurdy TE; Gibbs JM; Kelman JA
Pharmacoepidemiol Drug Saf; 2011 Jul; 20(7):684-8. PubMed ID: 21847800
[TBL] [Abstract][Full Text] [Related]
17. Pattern recognition in health insurance claims databases.
Walker AM
Pharmacoepidemiol Drug Saf; 2001; 10(5):393-7. PubMed ID: 11802583
[TBL] [Abstract][Full Text] [Related]
18. Using healthcare claims data for outcomes research and pharmacoeconomic analyses.
Birnbaum HG; Cremieux PY; Greenberg PE; LeLorier J; Ostrander JA; Venditti L
Pharmacoeconomics; 1999 Jul; 16(1):1-8. PubMed ID: 10539118
[TBL] [Abstract][Full Text] [Related]
19. Approach to addressing missing data for electronic medical records and pharmacy claims data research.
Bounthavong M; Watanabe JH; Sullivan KM
Pharmacotherapy; 2015 Apr; 35(4):380-7. PubMed ID: 25884526
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the impact of unmeasured confounding with internal validation data: an example cost evaluation in type 2 diabetes.
Faries D; Peng X; Pawaskar M; Price K; Stamey JD; Seaman JW
Value Health; 2013; 16(2):259-66. PubMed ID: 23538177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
